Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1115

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 4
Chunk 1115
---
) 
     (3,813,800)
  
    Unrealized Foreign Currency Translation (Loss) Gain 
     (90) 
     61,853 
  
    Total Comprehensive Loss 
     (7,955,753) 
     (3,751,947)

    Net Loss – Noncontrolling Interest 
     (8,556) 
     (48,098)
  
    Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (7,947,197) 
     (3,703,849)

    Cumulative Dividends on Series A Preferred Stock 
     (483,301) 
     (220,714)
  
    Net  Loss - attributed to common stockholders 
    $(8,430,498) 
    $(3,924,563)

    Net Loss per Common Share: 

    Basic and Diluted 
    $(18.55) 
    $(59.18)
  
    Weighted Average Number of Common Shares Outstanding 

    Basic and Diluted 
     454,582  
     66,314 

See accompanying notes to these consolidated
financial statements which are an integral part of these consolidated financial statements.

F-4

60 DEGREES PHARMACEUTICALS,
INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’
EQUITY 

    For
    the Year Ended December 31, 2024 

    Series
    A 
    Preferred Stock  
    Common
    
    Stock(1)  
    Additional
    Paid-In  
    Accumulated  
    Accumulated
    Other Comprehensive  
    Total
    
    Shareholders’
    Equity
    Attributable  
    Noncontrolling
                                                                                Interest
                                            on  
    Total
    Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Capital(1)  
    Deficit  
    Income
    (Loss)  
    to
    60P  
    Shareholders  
    Equity 
  
    Balance—December
    31, 2023 
     78,803  
    $9,858,040  
     96,847  
    $10  
    $27,457,373  
    $(32,580,850) 
    $135,561  
    $4,870,